Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Wedbush to hold a virtual conference » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
ABUS

Arbutus Biopharma

$3.44 /

-0.21 (-5.75%)

, BHVN

Biohaven Pharmaceutical

$59.86 /

-2.09 (-3.37%)

, IDRA

Idera Pharmaceuticals

$2.17 /

-0.04 (-1.81%)

, ALNA

Allena Pharmaceuticals

$1.40 /

-0.08 (-5.41%)

, CLSD

Clearside Biomedical

$1.72 /

-0.07 (-3.91%)

, VIE

Viela Bio

$36.02 /

-1.94 (-5.11%)

, AQST

Aquestive Therapeutics

$6.60 /

-0.35 (-5.04%)

, LQDA

Liquidia Technologies

$5.40 /

-0.48 (-8.16%)

, UTHR

United Therapeutics

$109.46 /

-1.49 (-1.34%)

, NTLA

Intellia Therapeutics

$19.53 /

-0.89 (-4.36%)

, KURA

Kura Oncology

$20.66 /

-0.67 (-3.14%)

, NBRV

Nabriva Therapeutics

$0.72 /

-0.0096 (-1.32%)

, MYOK

MyoKardia

$101.01 /

-3.86 (-3.68%)

, MRUS

Merus

$12.99 /

-0.23 (-1.74%)

, RCUS

Arcus Biosciences

$22.99 /

+0.03 (+0.13%)

, RARE

Ultragenyx

$82.73 /

-2.34 (-2.75%)

, MRSN

Mersana Therapeutics

$18.52 /

-1.52 (-7.58%)

, KALA

Kala Pharmaceuticals

$8.94 /

-0.3 (-3.25%)

, FENC

Fennec

$6.66 /

-3.48 (-34.32%)

, FPRX

Five Prime

$4.76 /

-0.4 (-7.75%)

, STRO

Sutro Biopharma

$8.49 /

+0.03 (+0.35%)

, SURF

Surface Oncology

$5.92 /

-0.04 (-0.67%)

, SWTX

SpringsWorks Therapeutics

$44.36 /

-1.1 (-2.42%)

, ISEE

Iveric bio

$4.39 /

-0.145 (-3.20%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$12.99 /

-0.23 (-1.74%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$6.66 /

-3.48 (-34.32%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$36.02 /

-1.94 (-5.11%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

SWTX SpringsWorks Therapeutics
$44.36 /

-1.1 (-2.42%)

SURF Surface Oncology
$5.92 /

-0.04 (-0.67%)

STRO Sutro Biopharma
$8.49 /

+0.03 (+0.35%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRUS Merus
$12.99 /

-0.23 (-1.74%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KURA Kura Oncology
$20.66 /

-0.67 (-3.14%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FPRX Five Prime
$4.76 /

-0.4 (-7.75%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

CLSD Clearside Biomedical
$1.72 /

-0.07 (-3.91%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ALNA Allena Pharmaceuticals
$1.40 /

-0.08 (-5.41%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

RARE Ultragenyx
$82.73 /

-2.34 (-2.75%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

UTHR United Therapeutics
$109.46 /

-1.49 (-1.34%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NTLA Intellia Therapeutics
$19.53 /

-0.89 (-4.36%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MYOK MyoKardia
$101.01 /

-3.86 (-3.68%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

ISEE Iveric bio
$4.39 /

-0.145 (-3.20%)

IDRA Idera Pharmaceuticals
$2.17 /

-0.04 (-1.81%)

FENC Fennec
$6.66 /

-3.48 (-34.32%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

AQST Aquestive Therapeutics
$6.60 /

-0.35 (-5.04%)

ABUS Arbutus Biopharma
$3.44 /

-0.21 (-5.75%)

RCUS Arcus Biosciences
$22.99 /

+0.03 (+0.13%)

NBRV Nabriva Therapeutics
$0.72 /

-0.0096 (-1.32%)

MRSN Mersana Therapeutics
$18.52 /

-1.52 (-7.58%)

LQDA Liquidia Technologies
$5.40 /

-0.48 (-8.16%)

KALA Kala Pharmaceuticals
$8.94 /

-0.3 (-3.25%)

BHVN Biohaven Pharmaceutical
$59.86 /

-2.09 (-3.37%)

Tuesday
Conference/Events
Wedbush to hold a virtual conference » 08:35
08/11/20
08/11
08:35
08/11/20
08:35
ABUS

Arbutus Biopharma

$3.65 /

-0.13 (-3.44%)

, BHVN

Biohaven Pharmaceutical

$61.95 /

-5.72 (-8.45%)

, IDRA

Idera Pharmaceuticals

$2.21 /

+0.12 (+5.74%)

, ALNA

Allena Pharmaceuticals

$1.48 /

-0.015 (-1.00%)

, CLSD

Clearside Biomedical

$1.79 /

+0.035 (+1.99%)

, VIE

Viela Bio

$37.96 /

+0.79 (+2.13%)

, AQST

Aquestive Therapeutics

$6.95 /

+0.66 (+10.49%)

, LQDA

Liquidia Technologies

$5.88 /

-0.35 (-5.62%)

, UTHR

United Therapeutics

$110.95 /

-1.84 (-1.63%)

, NTLA

Intellia Therapeutics

$20.42 /

+0.63 (+3.18%)

, KURA

Kura Oncology

$21.33 /

+0.95 (+4.66%)

, NBRV

Nabriva Therapeutics

$0.73 /

-0.005 (-0.68%)

, MYOK

MyoKardia

$104.87 /

+1.36 (+1.31%)

, MRUS

Merus

$13.22 /

+0.02 (+0.15%)

, RCUS

Arcus Biosciences

$22.96 /

+1.18 (+5.42%)

, RARE

Ultragenyx

$85.07 /

+0.37 (+0.44%)

, MRSN

Mersana Therapeutics

$20.04 /

-0.23 (-1.13%)

, KALA

Kala Pharmaceuticals

$9.24 /

+0.35 (+3.94%)

, FENC

Fennec

$10.14 /

+1.14 (+12.67%)

, FPRX

Five Prime

$5.16 /

-0.46 (-8.19%)

, STRO

Sutro Biopharma

$8.46 /

-0.05 (-0.59%)

, SURF

Surface Oncology

$5.96 /

-0.01 (-0.17%)

, SWTX

SpringsWorks Therapeutics

$45.46 /

+0.31 (+0.69%)

, ISEE

Iveric bio

$4.53 /

+0.11 (+2.49%)

Wedbush Pacgrow…

Wedbush Pacgrow Healthcare Virtual Conference will be held on August 11-12.

ShowHide Related Items >><<
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/24/20 Baird
Arbutus Biopharma downgraded to Neutral from Outperform at Baird
05/19/20 Wedbush
Arbutus Biopharma upgraded to Outperform at Wedbush following AB-729 data
BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

08/10/20 Piper Sandler
Piper says Biohaven post-earnings pullback a 'great buying opportunity'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
12/06/19 Wedbush
Allena Pharmaceuticals selloff 'overdone,' says Wedbush
CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Roth Capital
Clearside Biomedical initiated with a Buy at Roth Capital
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

07/15/20 Goldman Sachs
Viela Bio upgraded to Neutral from Sell at Goldman Sachs
06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/12/20 H.C. Wainwright
Viela Bio price target raised to $76 from $70 at H.C. Wainwright
06/09/20
Fly Intel: Top five analyst initiations
AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

07/30/20 Oppenheimer
United Therapeutics price target raised to $165 from $155 at Oppenheimer
06/25/20 Credit Suisse
United Therapeutics price target raised to $145 from $129 at Credit Suisse
06/25/20 H.C. Wainwright
United Therapeutics price target raised to $125 from $85 at H.C. Wainwright
04/07/20
United Therapeutics participates in a conference with JPMorgan
NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MRUS Merus
$13.22 /

+0.02 (+0.15%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

07/31/20 Barclays
Ultragenyx price target raised to $99 from $87 at Barclays
07/01/20 Truist
Ultragenyx price target raised to $88 from $82 at SunTrust
07/01/20 JPMorgan
Ultragenyx price target raised to $84 from $76 at JPMorgan
07/01/20 Wedbush
Ultragenyx price target raised to $91 from $83 at Wedbush
MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

06/24/20 BTIG
Mersana Therapeutics price target raised to $32 from $21 at BTIG
05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

07/23/20
Fly Intel: Top five analyst initiations
07/23/20 Northland
Kala Pharmaceuticals initiated with an Outperform at Northland
06/01/20 Oppenheimer
Kala Pharmaceuticals assumed with an Outperform at Oppenheimer
05/27/20 JPMorgan
Kala Pharmaceuticals assumed with an Overweight at JPMorgan
FENC Fennec
$10.14 /

+1.14 (+12.67%)

06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
06/04/20 Cantor Fitzgerald
Fennec initiated with an Overweight at Cantor Fitzgerald
05/15/20 H.C. Wainwright
Fennec price target lowered to $15 from $17 at H.C. Wainwright
FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

06/02/20 Citi
Ayala Pharmaceuticals initiated with a Buy at Citi
05/05/20 Barclays
SpringsWorks Therapeutics initiated with an Overweight at Barclays
03/19/20 H.C. Wainwright
SpringsWorks Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
03/04/20
Fly Intel: Top five analyst downgrades
ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
VIE Viela Bio
$37.96 /

+0.79 (+2.13%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

SWTX SpringsWorks Therapeutics
$45.46 /

+0.31 (+0.69%)

SURF Surface Oncology
$5.96 /

-0.01 (-0.17%)

STRO Sutro Biopharma
$8.46 /

-0.05 (-0.59%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRUS Merus
$13.22 /

+0.02 (+0.15%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KURA Kura Oncology
$21.33 /

+0.95 (+4.66%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FPRX Five Prime
$5.16 /

-0.46 (-8.19%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

CLSD Clearside Biomedical
$1.79 /

+0.035 (+1.99%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ALNA Allena Pharmaceuticals
$1.48 /

-0.015 (-1.00%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

  • 30
    Jun
  • 18
    Jun
  • 03
    Jun
  • 29
    May
  • 29
    May
  • 28
    May
  • 12
    May
  • 13
    May
  • 06
    May
  • 30
    Apr
  • 11
    Mar
  • 29
    Jan
  • 24
    Dec
  • 13
    Dec
  • 06
    Dec
  • 05
    Nov
  • 03
    Oct
  • 13
    Sep
RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

RARE Ultragenyx
$85.07 /

+0.37 (+0.44%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

UTHR United Therapeutics
$110.95 /

-1.84 (-1.63%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NTLA Intellia Therapeutics
$20.42 /

+0.63 (+3.18%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MYOK MyoKardia
$104.87 /

+1.36 (+1.31%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

ISEE Iveric bio
$4.53 /

+0.11 (+2.49%)

IDRA Idera Pharmaceuticals
$2.21 /

+0.12 (+5.74%)

FENC Fennec
$10.14 /

+1.14 (+12.67%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

AQST Aquestive Therapeutics
$6.95 /

+0.66 (+10.49%)

ABUS Arbutus Biopharma
$3.65 /

-0.13 (-3.44%)

RCUS Arcus Biosciences
$22.96 /

+1.18 (+5.42%)

NBRV Nabriva Therapeutics
$0.73 /

-0.005 (-0.68%)

MRSN Mersana Therapeutics
$20.04 /

-0.23 (-1.13%)

LQDA Liquidia Technologies
$5.88 /

-0.35 (-5.62%)

KALA Kala Pharmaceuticals
$9.24 /

+0.35 (+3.94%)

BHVN Biohaven Pharmaceutical
$61.95 /

-5.72 (-8.45%)

Over a week ago
Hot Stocks
Intellia Therapeutics expects cash to fund expenses through next 24 months » 07:42
08/06/20
08/06
07:42
08/06/20
07:42
NTLA

Intellia Therapeutics

$19.67 /

+0.14 (+0.72%)

Intellia expects that its…

Intellia expects that its cash, cash equivalents and marketable securities as of June 30, 2020 will enable the Company to fund its anticipated operating expenses and capital expenditure requirements at least through the next 24 months. This expectation excludes any strategic use of capital not currently in the Company's base-case planning assumptions.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

  • 03
    Jun
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

Earnings
Intellia Therapeutics reports Q2 EPS (61c), consensus (69c) » 07:41
08/06/20
08/06
07:41
08/06/20
07:41
NTLA

Intellia Therapeutics

$19.67 /

+0.14 (+0.72%)

Reports Q2 revenue $5.1M,…

Reports Q2 revenue $5.1M, consensus $8.54M. "We are very pleased to announce our first regulatory submission to initiate a Phase 1 study of NTLA-2001, which is an important milestone as we deliver on our mission to develop curative, CRISPR/Cas9-based treatments for severe diseases. Our CTA keeps us on track to dose our first ATTR patient by year-end and is a critical step in executing our global development strategy for the first systemically delivered CRISPR-based therapy to enter clinical trial," said Intellia President and Chief Executive Officer, John Leonard, M.D. "With our recently expanded collaboration with Regeneron and subsequent financing, we are well-capitalized to advance our initial wave of development programs and continue our work developing innovative modular platform capabilities."

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

  • 03
    Jun
NTLA Intellia Therapeutics
$19.67 /

+0.14 (+0.72%)

Hot Stocks
GEMoaB announces research collaboration and license agreement with Intellia » 08:05
07/20/20
07/20
08:05
07/20/20
08:05
NTLA

Intellia Therapeutics

$21.59 /

+0.18 (+0.84%)

GEMoaB announced that it…

GEMoaB announced that it has entered into a research collaboration and license agreement with Intellia. The companies will conduct joint research to combine GEMoaB's proprietary RevCAR technology platform with Intellia's proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies for hard-to-treat cancers and inflammatory diseases. The companies will focus on immunotherapies directed against a selected number of targets. Under the terms of the agreement, GEMoaB will receive payments for each product based on target reservation and selection, achievement of regulatory, clinical and commercial milestones as well as tiered royalties based on net sales. Intellia will lead the research collaboration, and be responsible for clinical development and commercialization.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$21.59 /

+0.18 (+0.84%)

NTLA Intellia Therapeutics
$21.59 /

+0.18 (+0.84%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$21.59 /

+0.18 (+0.84%)

  • 03
    Jun
NTLA Intellia Therapeutics
$21.59 /

+0.18 (+0.84%)

Over a month ago
Hot Stocks
Intellia Therapeutics, Teneobio enter research collaboration for cell therapies » 08:11
06/08/20
06/08
08:11
06/08/20
08:11
NTLA

Intellia Therapeutics

$20.34 /

-0.26 (-1.26%)

Teneobio announced that…

Teneobio announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics to use Teneobio's Heavy Chain Antibodies for Intellia's next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs against targets which can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization. Under the terms of the agreement, Teneobio will receive an upfront payment and will be eligible to receive additional payments for the achievement of certain preclinical, clinical, regulatory, and commercial milestones. Teneobio would also receive royalties on potential future sales.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$20.34 /

-0.26 (-1.26%)

NTLA Intellia Therapeutics
$20.34 /

-0.26 (-1.26%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$20.34 /

-0.26 (-1.26%)

NTLA Intellia Therapeutics
$20.34 /

-0.26 (-1.26%)

Syndicate
Intellia Therapeutics 5.48M share Secondary priced at $18.25 » 21:02
06/02/20
06/02
21:02
06/02/20
21:02
NTLA

Intellia Therapeutics

$20.27 /

-0.67 (-3.20%)

The deal size was…

The deal size was increased from $75M to $100M and priced below the last closing price of $20.26. Goldman Sachs, Jefferies and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$20.27 /

-0.67 (-3.20%)

NTLA Intellia Therapeutics
$20.27 /

-0.67 (-3.20%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$20.27 /

-0.67 (-3.20%)

  • 03
    Jun
NTLA Intellia Therapeutics
$20.27 /

-0.67 (-3.20%)

On The Fly
Fly Intel: After-Hours Movers » 19:07
06/01/20
06/01
19:07
06/01/20
19:07
NTLA

Intellia Therapeutics

$20.94 /

+3.43 (+19.59%)

, IDYA

Ideaya Biosciences

$10.80 /

+1.03 (+10.54%)

, INVH

Invitation Homes

$27.95 /

+1.64 (+6.23%)

, OSUR

OraSure

$14.12 /

-0.48 (-3.29%)

, ENS

EnerSys

$65.32 /

+1.9 (+3.00%)

, CSWC

Capital Southwest

$14.92 /

+0.935 (+6.69%)

, SALM

Salem Media

$0.99 /

+0.0935 (+10.45%)

, PUMP

ProPetro Holding

$5.00 /

+0.05 (+1.01%)

, PRCP

Perceptron

$3.09 /

+0.1 (+3.34%)

, WU

Western Union

$20.75 /

+0.72 (+3.59%)

, MGI

MoneyGram

$2.60 /

+0.185 (+7.66%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WU Western Union
$20.75 /

+0.72 (+3.59%)

SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

OSUR OraSure
$14.12 /

-0.48 (-3.29%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

04/06/20
Fly Intel: Top five analyst initiations
04/06/20 H.C. Wainwright
Ideaya Biosciences initiated with a Buy at H.C. Wainwright
03/13/20
Fly Intel: Top analyst initiations
03/13/20 Roth Capital
Ideaya Biosciences initiated with a Buy at Roth Capital
INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

06/01/20 Mizuho
Invitation Homes price target raised to $28 from $25 at Mizuho
05/14/20 RBC Capital
Invitation Homes price target lowered to $29 from $31 at RBC Capital
04/29/20 Credit Suisse
Invitation Homes price target lowered to $27 from $32 at Credit Suisse
04/29/20 Mizuho
Invitation Homes upgraded to Buy on relative valuation at Mizuho
OSUR OraSure
$14.12 /

-0.48 (-3.29%)

04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
ENS EnerSys
$65.32 /

+1.9 (+3.00%)

04/02/20 Oppenheimer
EnerSys price target lowered to $75 from $80 at Oppenheimer
CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

03/17/20 National Securities
Capital Southwest upgraded to Buy from Neutral at National Securities
03/03/20 National Securities
Capital Southwest downgraded to Neutral from Buy at National Securities
12/12/19 Raymond James
Capital Southwest initiated with an Outperform at Raymond James
12/12/19 Raymond James
Capital Southwest initiated with an Outperform at Raymond James
SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

03/25/20 JPMorgan
Liberty Oilfield Services downgraded to Neutral with $5 target at JPMorgan
03/19/20 Wolfe Research
ProPetro Holding downgraded to Peer Perform from Outperform at Wolfe Research
03/19/20 Barclays
ProPetro Holding downgraded to Equal Weight from Overweight at Barclays
03/17/20 B. Riley FBR
B. Riley FBR says be 'highly selective' in Oilfield Services, downgrades three
PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

03/19/20 B. Riley FBR
B. Riley FBR downgrades four names with exposure to auto manufacturers
03/19/20 B. Riley FBR
Perceptron downgraded to Neutral from Buy at B. Riley FBR
WU Western Union
$20.75 /

+0.72 (+3.59%)

04/08/20 Wells Fargo
Western Union downgraded to Underweight from Equal Weight at Wells Fargo
04/06/20 Barclays
Western Union price target lowered to $18 from $25 at Barclays
04/03/20 Northcoast
Northcoast cuts estimates for MoneyGram and Western Union
04/02/20 Truist
Western Union price target lowered to $18 from $27 at SunTrust
MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

04/06/20 Barclays
MoneyGram price target lowered to $1 from $2 at Barclays
03/24/20 Northland
Northland downgrades MoneyGram to Market Perform on coronavirus lockdowns
03/24/20 Northland
MoneyGram downgraded to Market Perform from Outperform at Northland
WU Western Union
$20.75 /

+0.72 (+3.59%)

SALM Salem Media
$0.99 /

+0.0935 (+10.45%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

PRCP Perceptron
$3.09 /

+0.1 (+3.34%)

OSUR OraSure
$14.12 /

-0.48 (-3.29%)

NTLA Intellia Therapeutics
$20.94 /

+3.43 (+19.59%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

IDYA Ideaya Biosciences
$10.80 /

+1.03 (+10.54%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

  • 03
    Jun
  • 03
    Jun
  • 02
    Jun
WU Western Union
$20.75 /

+0.72 (+3.59%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

INVH Invitation Homes
$27.95 /

+1.64 (+6.23%)

WU Western Union
$20.75 /

+0.72 (+3.59%)

PUMP ProPetro Holding
$5.00 /

+0.05 (+1.01%)

MGI MoneyGram
$2.60 /

+0.185 (+7.66%)

ENS EnerSys
$65.32 /

+1.9 (+3.00%)

CSWC Capital Southwest
$14.92 /

+0.935 (+6.69%)

Syndicate
Intellia Therapeutics announces $75M common stock offering » 16:01
06/01/20
06/01
16:01
06/01/20
16:01
NTLA

Intellia Therapeutics

$21.13 /

+3.62 (+20.67%)

Intellia Therapeutics…

Intellia Therapeutics announced that it has commenced an underwritten public offering of $75M of shares of its common stock. Goldman Sachs, Jefferies, and SVB Leerink are acting as joint book-running managers for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$21.13 /

+3.62 (+20.67%)

NTLA Intellia Therapeutics
$21.13 /

+3.62 (+20.67%)

06/01/20 Wedbush
Intellia Therapeutics price target raised to $20 from $16 at Wedbush
02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
NTLA Intellia Therapeutics
$21.13 /

+3.62 (+20.67%)

Recommendations
Intellia Therapeutics price target raised to $20 from $16 at Wedbush » 12:54
06/01/20
06/01
12:54
06/01/20
12:54
NTLA

Intellia Therapeutics

$19.78 /

+2.27 (+12.96%)

Wedbush analyst David…

Wedbush analyst David Nierengarten raised the firm's price target on Intellia Therapeutics (NTLA) to $20 from $16 and keeps a Neutral rating on the shares after the company announced an expanded collaboration with Regeneron (REGN) to develop CRISPR/Cas9-based treatments to include an additional five in vivo gene targets. Nierengarten views the expanded deal as a favorable extension of the existing collaboration, saying the financial terms for Intellia are attractive and alleviates a meaningful degree of dilutive financing risk for the company. The analyst views Intellia's programs as fully valued at these levels.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$19.78 /

+2.27 (+12.96%)

NTLA Intellia Therapeutics
$19.78 /

+2.27 (+12.96%)

02/28/20 Oppenheimer
Intellia making progress in in-vivo editing, says Oppenheimer
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/14/20 Wedbush
Intellia Therapeutics downgraded to Neutral from Outperform at Wedbush
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
NTLA Intellia Therapeutics
$19.78 /

+2.27 (+12.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.